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During the past 3 decades, cardiologists have been earnestly 
searching for more effective methods to perform myocardial 
revascularization or deliver pharmacologic agents to protect 
or salvage acutely ischemic myocardium. In recent years, 
coronary artery bypass surgery, thrombolysis and percuta-
neous transluminal balloon angioplasty have become univer-
sally accepted methods for revascularization of the acutely 
ischemic myocardium. Other invasive technologies are cur-
rently under investigation for the treatment of acute isch-
emic syndromes. Among them, coronary sinus retroperfu-
sion utilizes the coronary veins and venoarterial capillary 
plexus for retrograde delivery of arterial blood or pharma-
cologic agents, or both, to the ischemic tissue. 
The objective of this Seminar is three-fold: 1) to review 
the current status of recently developed coronary sinus 
interventional technologies; 2) to discuss the mechanisms of 
myocardial retroperfusion and retroinfusion of pharmaco-
logic agents, as well as retrograde cardioplegia for myocar-
dial protection during surgery; and 3) to propose clinical 
applications of these techniques. 
In this comprehensive Seminar, we have invited investi-
gators to report their recent experimental data and initial 
clinical experiences of novel "coronary venous support 
systems." All reports included in this Seminar were peer 
reviewed by recognized authorities for fair assessment of the 
different basic scientific viewpoints or clinical experiences of 
the contributors. 
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Historic Background 
The use of the coronary veins to retroperfuse the jeopar-
dized ischemic heart dates. back to the 1940s when Claude 
Beck and his associates (1) reported the first of a series of 
approximately 200 patients operated on for symptomatic 
coronary artery disease using a systemic arterial-coronary 
venous anastomosis for retrograde myocardial perfusion. 
Although this procedure initially appeared successful, it was 
later abandoned, mostly because of its long-term complica-
tions. It became clear that their surgical retroperfusion 
technique lacked appropriate coronary venous drainage, 
which caused myocardial edema and hemorrhage, that be-
came major drawbacks of the so-called Beck operation. 
Catheter-based synchronized coronary venous retroper-
fusion has been developed in our laboratory for the past 17 
years. This system features critical phasic elements, namely, 
retrograde pumping of arterial blood across the venoarterial 
capillary plexus during diastole and appropriate drainage of 
coronary venous outflow during systole (2). 
In the past decade, a number of experimental studies 
(3-10) have demonstrated that after acute coronary occlu-
sion, synchronized diastolic retroperfusion can promptly 
improve ischemic zone myocardial function and reduce 
infarct size in both the dog (3-8) and baboon (9,10). More 
recently there have been significant technical improvements 
in the retroperfusion pump for clinical application, particu-
larly the development of a gas-driven balloon catheter, 
which now permits delivery up to 250 mUmin of autologous 
arterial blood in diastole. 
Part I 
Part I of the Seminar includes four original contributions 
on coronary venous retroperfusion that report on both 
experimental and clinical trials for support or rescue of 
jeopardized regionally ischemic myocardium. 
Nutrient myocardial blood ftow and metabolism. O'Byrne 
et al. (11) present data on regional myocardial nutrient flow 
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and metabolism during retroperfusion after acute coronary 
occlusion measured by positron emission tomography. This 
study provides novel in vivo technology for assessing the 
efficacy of coronary venous retroperfusion. It also elucidates 
previously unanswered questions concerning potential ben-
efits of synchronized coronary venous retroperfusion on 
both myocardial perfusion and metabolic function. 
Clinical trials during elective coronary angioplasty. Re-
sults of coronary venous retroperfusion support in patients 
undergoing elective balloon angioplasty of the left anterior 
descending coronary artery are presented by Kar et al. (12). 
Their study focuses on feasibility, safety and efficacy of 
retroperfusion using chest pain and other markers of myo-
cardial ischemia, such as electrocardiographic ST segment 
alterations and two-dimensional echocardiographic ischemic 
wall motion abnormalities. 
Clinical trials in high risk angioplasty. Costantini et al. 
(13) report their initial experience using coronary venous 
retroperfusion for support of ischemic myocardium in pa-
tients with unstable angina undergoing coronary balloon 
angioplasty. Their study provides valuable information on a 
high risk patient subset using invasive measurements for 
assessment of retroperfusion efficacy. 
Hypothermic retroperfusion. Wakida et al. (14) report on 
the efficacy of hypothermic synchronized retroperfusion of 
arterial blood in an open chest canine preparation. They 
provide detailed information on regional myocardial temper-
ature distribution during hypothermic retroperfusion and the 
impact of myocardial cooling on ultimate infarct size. They 
also discuss therapeutic potentials of percutaneous cooling 
of regionally ischemic myocardium using state of the art 
coronary venous retroperfusion technology. 
Part II 
Coronary venous retroinfusion of drug and cardioplegic 
solutions. Retroinfusion of cardioplegic solutions has been 
successfully used by surgeons for a number of years (15-18). 
Drug retroperfusion and retroinfusion in the ischemic beat-
ing heart were initially reported from the Corday Laboratory 
in 1982 (19). Since that time, pharmacokinetic principles of 
drug retroinfusion have been studied and catheter technol-
ogy has undergone successive and critical improvements 
with the objective of exploring the potentials of this inter-
vention in clinical practice. The Corday coronary venous 
triple lumen retroinfusion catheter (Retroperfusion Systems, 
Inc.) was recently developed for clinical use to provide a 
superior and safe method for local delivery of cardioactive 
pharmacologic agents into the beating heart. The second 
lumen allows concomitant inflation of the balloon at the tip 
of the catheter to hold the infusate and prevent drug regur-
gitation to the right atrium. The third lumen is used for 
continuous monitoring of coronary venous pressure. In this 
manner, the safety limits of coronary venous pressures can 
be controlled so that the peak pressure limit of 60 mm Hg is 
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not surpassed, avoiding damage to the coronary veins and 
surrounding myocardium (2). 
In the experimental setting, so far 14 pharmacologic 
agents given by coronary venous retroinfusion during coro-
nary artery occlusion have been tested and compared with 
the same amounts of drugs given by the systemic intrave-
nous route. Infarct-reducing agents such as oxygen free 
radical scavengers and thrombolytic agents as well as some 
antiarrhythmic agents proved to be more effective when 
given by the coronary venous route in these studies (20-24). 
The rationale for the use of this retrograde infusion 
system in acute regional myocardial ischemia is to provide 
local therapeutic concentrations of cardioprotective drugs 
that otherwise would not reach the jeopardized zone because 
of coronary arterial occlusion and reduced collateral flow to 
ischemic but still viable myocardium. Myocardial tissue 
assays reveal a tremendous drug accumulation in the isch-
emic zone after retroinfusion that may achieve particular 
benefit by using lesser (nontoxic) doses (25,26). 
Pharmacokinetics of drug retroinfusion. In the first report 
in this series (to be published in the next issue of the 
Journal), Ryden et al. (27) describe in detail the pharmaco-
kinetics of coronary venous drug retroinfusion using the 
beta-adrenergic blocking agent metoprolol as a tracer. They 
compare myocardial tissue concentrations of metoprolol 
given intravenously or anterogradely into the coronary ar-
tery (distal to the occlusion site) with retroinfusion of 
metoprolol by way of the coronary veins. It is clear from 
their experimental studies that significant myocardial drug 
accumulation can be rapidly achieved in the ischemic region 
by this technique. 
Retrograde cardioplegia. Menasche and Piwnica (28) pro-
vide a comprehensive review of their extensive experience 
with the use of retrograde cardioplegia for myocardial pro-
tection during valvular and coronary bypass surgery. They 
also compare the relative efficacy of retrograde versus 
anterograde cardioplegia in terms of recovery of cardiac 
function after surgery, as well as the incidence of perioper-
ative myocardial infarction. They emphasize that this tech-
nique has considerable advantages over conventional antero-
grade cardioplegia in specific classes of surgical candidates. 
Retroinfusion of the free oxygen radical scavenger defer-
oxamine. Kobayashi et al. (29) report on the use of coronary 
venous retroinfusion of the free radical scavenger deferox-
amine in pigs with acute coronary artery occlusion. Retroin-
fusion of this iron chelator before and during reperfusion was 
compared with the same amount of drug given intrave-
nously. Infarct size reduction occurred in animals given 
deferoxamine only by coronary venous retroinfusion. 
This coronary venous approach to drug delivery builds up 
concentrations of free radical scavengers in the ischemic 
myocardium before reperfusion, which have been consis-
tently shown to reduce infarct size in experimental studies 
(22-24) as opposed to no appreciable beneficial effects when 
the drugs were given systemically. The explanation for such 
consistent findings may be simply related to higher myocar-
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dial tissue drug concentrations achieved by retroinfusion in 
the presence of coronary artery occlusion. Because oxygen 
free radical scavengers have a local rather than a systemic 
effect, this may indeed explain previously reported contra-
dictory results (30,31) about variable effects of these agents 
on myocardial infarct size. 
Retroinfusion of thrombolytic agents. Miyazaki et al. (32) 
report on the use of coronary venous compared with sys-
temic intravenous infusion of recombinant tissue-type plas-
minogen activator (rt-PA) in dogs with thrombotic coronary 
artery occlusion. Their study shows that thrombolysis oc-
curs more rapidly and more consistently after rt-PA retroin-
fusion. Their results may have some important clinical 
implications, particularly because adjunctive therapy to 
reperfusion can be retroinfusion concomitantly with throm-
bolytic agents, providing more powerful beneficial effects of 
reperfusion. Moreover, this technique offers the potential 
advantage of using continued local infusion, which could be 
important in preventing reocclusion. 
Potential of Coronary Sinus Interventions 
and Clinical Implications 
Clinical applications. Why publish a seminar on coronary 
sinus interventions in view of the recent advances in intra-
coronary arterial interventions and thrombolysis? The ini-
tially foreseeable applications of retroperfusion and other 
coronary sinus interventions must be put into perspective 
with other modern interventional cardiologic methods. Pro-
tection of ischemic myocardium during complex intracoro-
nary artery interventions is clinically relevant (33-35) and 
prevention of restenosis after angioplasty requires innova-
tive strategies, including new drug delivery techniques that 
might counteract the development of early vessel restenosis, 
a major drawback of angioplasty. 
In terms of the potential use of this and other technologies 
in patients with acute myocardial infarction, it is becoming 
clear that systemic intravenous thrombolytic therapy is not 
the definitive answer for the treatment of acute infarction 
(36). Although reduction in the 1 year mortality rate seems 
unquestionable (37), the majority of survivors of acute 
myocardial infarction treated with intravenous thrombolytic 
agents alone leave the hospital with a relatively large area of 
irreversible myocardial damage, which may be related not 
only to lack of early reperfusion (which occurs in as many as 
40% of patients), but also to incomplete reperfusion, early 
reocclusion, "reperfusion injury" or a combination of these 
factors. Indeed, a recent analysis of the Italian GISSI trial 
has shown an increased mortality during the 1 st day after 
thrombolysis (38). Moreover, only a fraction of patients with 
acute myocardial infarction appear to be eligible for this 
therapy. Unfortunately, thrombolysis itself activates throm-
bin (39,40) and there is recent evidence (41) suggesting that 
higher doses of rt-PA in patients with acute myocardial 
infarction are associated with enhanced thrombin genera-
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tion, which may account for early vessel rethrombosis or 
resistance to clot lysis. 
Early vessel reocclusion is also not infrequent after me-
chanical recanalization alone or in combination with throm-
bolytic therapy (42). Thus, the need for adjunctive therapy to 
intravenous thrombolysis or angioplasty in patients with 
acute myocardial infarction is becoming an accepted reality 
to many cardiologists and should be more consistently 
investigated if the goal of maximal myocardial salvage with 
minimal necrosis is to be achieved. The coronary sinus is a 
logical and viable alternative route to achieve such goals and 
its safety and benefits should be fully explored (43,44). 
Other specific clinical applications of this technology 
should also be investigated. For example, it may have a role 
in patients who develop myocardial ischemia or coronary 
occlusion during or immediately after noncardiac surgery, 
for whom adequate therapy is still not available. Hajduczki 
et al. (45) recently suggested the use of retroperfusion for 
diagnosis of hibernating myocardium in patients with 
chronic postischemic left ventricular dysfunction. Obvi-
ously, more studies are needed to assess the value of 
retroperfusion in such specific clinical conditions. 
Safety and limitations. The clinical trials reported in this 
Seminar are the results of the initial experiences of the 
individual contributors. As is the case with any invasive 
technology, skill and dexterity in retroperfusion methods 
require a learning period. Furthermore, there are inherent 
limitations of analytic methods utilized to assess retroperfu-
sion efficacy clinically that must be considered when inter-
preting these initial results. Until today safety and efficacy of 
the current retroperfusion pump has been well documented 
in about 260 patients included in different protocols world-
wide, the two most recent from Allegheny General Hospital 
and from Osaka by Nishida et al. using the system during 
high risk coronary angioplasty (12,13,46,47,48). 
It is our expectation that this Seminar will improve 
understanding of the mechanisms of coronary venous ret-
roperfusion and retroinfusion and stimulate continued re-
search and discussions on the potential usefulness of these 
technologies in modern cardiology practice. 
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